Kiromic Biopharma Inc Stock Price, News & Analysis

Kiromic BioPharma (OTCQB: KRBP) is advancing its Deltacel-01 Phase 1 clinical trial to the Expansion Phase following a positive assessment from the Safety Monitoring Committee. The trial evaluates Deltacel™, an allogeneic, off-the-shelf, Gamma Delta T-cell therapy for stage 4 metastatic non-small cell lung cancer patients who have failed standard therapies. The company plans to begin enrolling patients in the Expansion Phase in September, adding nine more patients to the trial.

The fifth patient in Deltacel-01 completed their 30-day visit with a favorable safety profile and no dose-limiting toxicities. Kiromic expects to report early efficacy data from this patient's two-month follow-up in August. The trial's progress marks a significant milestone in validating Kiromic's innovative gamma delta approach to cancer treatment.

Kiromic BioPharma (OTCQB: KRBP) has provided updates on its Deltacel-01 Phase 1 clinical trial, which focuses on advanced non-small cell lung cancer (NSCLC) patients non-responsive to standard treatments. The trial features Deltacel (KB-GDT-01), an allogeneic Gamma Delta T-cell therapy. Patients three and four showed stable disease at follow-ups with no dose-limiting toxicities. The second patient had a complete response in brain metastasis but later detected a new subcutaneous metastasis; a new treatment protocol has been approved by the FDA. Kiromic has also submitted a Fast Track designation request to the FDA, possibly accelerating Deltacel's development. Additionally, a fifth patient completed their safety visit with no toxicities, while the sixth patient is anticipated to enroll in July.

Kiromic BioPharma (OTCQB: KRBP) has released promising six-month follow-up results for the first patient in the Deltacel-01 Phase 1 clinical trial. This trial assesses Deltacel™ (KB-GDT-01), an off-the-shelf Gamma Delta T-cell therapy for stage 4 metastatic non-small cell lung cancer (NSCLC). The patient showed a 13% tumor reduction and no new lesions, resulting in six-month progression-free survival. No dose-limiting toxicities were reported, confirming Deltacel's safety. Kiromic plans to report further long-term results by the end of June and continues to enroll new patients in the trial.

Kiromic BioPharma (OTCQB: KRBP) reported favorable six-week results from the fourth patient in its Deltacel-01 Phase 1 clinical trial. This trial evaluates the allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy, Deltacel™ (KB-GDT-01), in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who didn't respond to standard treatments. Preliminary results show an 8.5% reduction in tumor size and no new metastatic disease sites, indicating promising early efficacy. The patient also experienced improved quality of life, including discontinuation of prescription pain medications. CEO Pietro Bersani expressed optimism about these initial findings and the upcoming results from the remaining patients in the second cohort, expected in June.

Kiromic BioPharma has announced that UPMC in Pittsburgh, PA, is now the fourth clinical trial site for their Deltacel-01 Phase 1 trial. This trial evaluates Deltacel™ (KB-GDT-01), an allogeneic, off-the-shelf, Gamma Delta T-cell therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC). Dr. Jason J. Luke, a leading expert in immuno-oncology, will serve as the principal investigator at UPMC. Preliminary safety and tolerability data from the fourth patient in Deltacel-01 are favorable, with early efficacy data expected by the end of May. The company plans to enroll the fifth and sixth patients in May and June, respectively, and activate one more trial site later this quarter.